Journal
CLINICAL CANCER RESEARCH
Volume 12, Issue 24, Pages 7232-7241Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-06-0658
Keywords
-
Categories
Funding
- NCI NIH HHS [5T32CA009207, R21-CA115051, K08-CA097980] Funding Source: Medline
Ask authors/readers for more resources
In 2004, several investigators reported that somatic mutations in the epidermal growth factor receptor gene were associated with clinical responses to erlotinib and gefitinib in patients with non-small cell lung cancer. Since then, multiple groups have examined the biological properties that such mutations confer as well as the clinical relevance of these mutations in patients with non-small cell lung cancer. Although a tremendous amount of knowledge has been gained in the past 2 years, there remain a number of important epidemiologic, biological, and clinical questions.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available